Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 42

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 42
---
 its option from time to time until July 2025, to purchase up to a maximum ownership of 35% of our then-outstanding voting common stock. The Investor Rights Agreement provides for a three-year standstill, three-year lockup and the right to
designate two individuals to be appointed to

1

our Board of Directors. As of December 31, 2022, Gilead held approximately 18.9% of our outstanding common stock. Gilead has indicated that it may seek to maintain its ownership position through open market transactions and/or by potentially engaging us in a private transaction. We cannot guarantee that Gilead will maintain its ownership position or that we will enter into any new agreements for any such private transactions during the term of any offering. Taiho In 2017, we entered into an Option and License Agreement with Taiho Pharmaceutical Co., Ltd., or Taiho, pursuant to which Taiho was granted time-limited options to exclusively license for Japan and certain other territories in Asia (excluding China) the development and commercialization rights to each of our programs that arose over a five-year period, which ended in September 2022. As of December 31, 2022, Taiho has licenses to our adenosine receptor antagonist program (including etrumadenant), anti-PD-1 program (including zimberelimab) and anti-TIGIT program (including domvanalimab and AB308). Other Licenses, Collaborations and R&D Arrangements We in-licensed rights to zimberelimab and anti-CD39 antibodies from WuXi Biologics Ireland Limited, and in-licensed rights to products that include an anti-TIGIT antibody, including domvanalimab, from Abmuno Therapeutics LLC. We also have a clinical collaboration agreement with AstraZeneca plc for the PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 non-small cell lung cancer and an agreement with BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Corporate Information We were incorporated in Delaware on April 30, 2015. Our principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545, and our telephone number is (510) 694-6200. Our website address is www.arcusbio.com. The information on, or that can be accessed through, our website is not part of this prospectus